PathoQuestSHS: investment, 202111 financing round Series B totalling up to 15m incl new + lead investor SHS Capital - [LSE] Life-Sciences-Europe.com - The European Life Sciences Web Portal
Summary
It will support the development of PathoQuests US site (Wayne, PA), the expansion of the portfolio of NGS-based quality control (QC) tests, and will accelerate its growth and market share worldwide. With its innovative NGS-based approach for the biosafety of biologics, PathoQuest will help biopharmaceutical companies in their quest to deliver advanced therapy medicinal products and vaccines more safely and more rapidly than ever to patients, stated Sascha Alilovic, Managing Partner at SHS Capital. To meet the leading market needs, PathoQuest is also expanding globally with a state-of-the-art facility located in Wayne, Pennsylvania, and is broadening its portfolio of NGS-based quality control solutions for the biosafety of biologics. We are pleased to complete this financing round since it enables PathoQuest to further establish its position as a leader of NGS-based quality control of cell and gene therapies, vaccines and other biologics, commented Jean-Francois Brepson, PathoQuests CEO. Turenne/SHAM was advised by Jérôme Chapron & Jeremie Lolmede from the law firm Chammas & Marcheteau, Marc Olivier Bévierre & Anne Moore from Cepton and Julien Trelhu from Repère group. Its teams, composed of 67 professionals, including 51 investors support more than 250 companies employing 23,000 people in the health, hospitality, new technology, distribution, and innovative services sectors.